Psychopathological Risk Assessment in Children with Hyperphenylalaninemia

Overview

Journal Children (Basel)

Specialty Health Services

Date 2022 Nov 11

PMID 36360407

Authors

Maria Cristina Risoleo

Margherita Siciliano

Luigi Vetri

Ilaria Bitetti

Anna Di Sessa

Marco Carotenuto

Francesca Annunziata

Daniela Concolino

Rosa Marotta

Affiliations

Soon will be listed here.

Abstract

Background: Phenylketonuria (PKU) is a rare congenital disorder caused by decreased metabolism of phenylalanine determining cerebral impairments. If untreated, PKU might lead to intellectual disability, seizures and behavioral disorders. The aim of this study is to provide a characterization of the psychopathological profile of a pediatric population diagnosed with PKU at newborn screening.

Methods: an accurate neuropsychological evaluation of 23 patients (aged 8-18 years) with hyperphenylalaninemia (defined as experimental group, EG) and in 23 age-matched healthy controls (defined as control group, CG) was performed using the Child and Adolescent Behavior Inventory (CABI) and Self-Administrated Psychiatric Scales for Children and Adolescents (SAFA) questionnaires.

Results: the CABI test showed significant differences for the sub-scales related to "Irritable mood", "Oppositional-provocative symptoms" and "ADHD" in the EG compared to CG ( = 0.014, = 0.032, and = 0.032, respectively). Patients with hyperphenylalaninemia also presented with significant differences both for anxiety disorder scale and depression scale of SAFA test than controls ( = 0.018 and = 0.009, respectively).

Conclusions: children and adolescents with early diagnosis of PKU showed a psychopathological risk profile characterized by an increased risk of experiencing symptoms such as mood deflection, anxiety, attention deficit, oppositional defiant behavior, and obsessive traits than healthy peers. Our findings highlighted the need of the inclusion of a neuropsychiatric evaluation in the management of these patients to improve their overall quality of life.

References

Loeber J . Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007; 30(4):430-8. DOI: 10.1007/s10545-007-0644-5. View

Weglage J, Pietsch M, Funders B, Koch H, Ullrich K . Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions?. Eur J Pediatr. 1996; 155(3):200-4. DOI: 10.1007/BF01953938. View

Griffiths P, Demellweek C, Fay N, Robinson P, Davidson D . Wechsler subscale IQ and subtest profile in early treated phenylketonuria. Arch Dis Child. 2000; 82(3):209-15. PMC: 1718264. DOI: 10.1136/adc.82.3.209. View

Gassio R, Artuch R, Vilaseca M, Fuste E, Boix C, Sans A . Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev Med Child Neurol. 2005; 47(7):443-8. DOI: 10.1017/s0012162205000861. View

Hoeksma M, Reijngoud D, Pruim J, de Valk H, Paans A, van Spronsen F . Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab. 2009; 96(4):177-82. DOI: 10.1016/j.ymgme.2008.12.019. View

Stemerdink B, Kalverboer A, van der Meere J, van der Molen M, Huisman J, de Jong L . Behaviour and school achievement in patients with early and continuously treated phenylketonuria. J Inherit Metab Dis. 2000; 23(6):548-62. DOI: 10.1023/a:1005669610722. View

van Spronsen F, Blau N, Harding C, Burlina A, Longo N, Bosch A . Phenylketonuria. Nat Rev Dis Primers. 2021; 7(1):36. PMC: 8591558. DOI: 10.1038/s41572-021-00267-0. View

Ashe K, Kelso W, Farrand S, Panetta J, Fazio T, de Jong G . Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments. Front Psychiatry. 2019; 10:561. PMC: 6748028. DOI: 10.3389/fpsyt.2019.00561. View

Sadek A, Hassan M, Mohammed N . Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years. Neuropsychiatr Dis Treat. 2018; 14:2551-2561. PMC: 6179721. DOI: 10.2147/NDT.S176198. View

10.

Cianchetti C, Pasculli M, Pittau A, Campus M, Carta V, Littarru R . Child and Adolescent Behavior Inventory (CABI): Standardization for Age 6-17 Years and First Clinical Application. Clin Pract Epidemiol Ment Health. 2017; 13:20-26. PMC: 5388793. DOI: 10.2174/1745017901713010020. View

11.

Anjema K, van Rijn M, Verkerk P, Burgerhof J, Heiner-Fokkema M, van Spronsen F . PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab. 2011; 104(3):231-4. DOI: 10.1016/j.ymgme.2011.05.017. View

12.

. Phenylketonuria (PKU): screening and management. NIH Consens Statement. 2002; 17(3):1-33. View

13.

Jusiene R, Kucinskas V . Psychological adjustment of children with congenital hypothyroidism and phenylketonuria as related to parental psychological adjustment. Medicina (Kaunas). 2004; 40(7):663-70. View

14.

Bilder D, Kobori J, Cohen-Pfeffer J, Johnson E, Jurecki E, Grant M . Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. Mol Genet Metab. 2017; 121(1):1-8. DOI: 10.1016/j.ymgme.2017.03.002. View

15.

Antshel K . ADHD, learning, and academic performance in phenylketonuria. Mol Genet Metab. 2010; 99 Suppl 1:S52-8. DOI: 10.1016/j.ymgme.2009.09.013. View

16.

Burnett S, Thompson S, Bird G, Blakemore S . Pubertal development of the understanding of social emotions: Implications for education. Learn Individ Differ. 2012; 21(6):681-689. PMC: 3219830. DOI: 10.1016/j.lindif.2010.05.007. View

17.

Shintaku H . Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab. 2002; 3(2):123-31. DOI: 10.2174/1389200024605145. View

18.

Antshel K, Waisbren S . Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol. 2003; 31(6):565-74. DOI: 10.1023/a:1026239921561. View

19.

Huijbregts S, de Sonneville L, van Spronsen F, Berends I, Licht R, Verkerk P . Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria. Neuropsychology. 2003; 17(3):369-79. DOI: 10.1037/0894-4105.17.3.369. View

20.

Smith I, Beasley M, Wolff O, Ades A . Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. J Pediatr. 1988; 112(3):403-8. DOI: 10.1016/s0022-3476(88)80320-2. View